RxDoctor Payments DataLook up a doctor →

Iyad Baker, MD

Family Medicine · Ridgefield Park, NJNPI 1730341322

Payments from drug & device makers

$76,531in general payments, 2019–2025

Across 441 payments — averaging $173.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$33K
  • Life Technologies Corporation$23K
  • BD$10K
  • Amgen$3K
  • AstraZeneca$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$983
  • plus $5K from 47 others

What the payments were for

  • Speaking & faculty fees$23,05875%
  • Food & beverage$7,65325%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,531 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$169,338
Medicare patients
394
Services billed
2,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide333$358,928
OzempicSemaglutide289$353,055
EliquisApixaban93$89,482
FarxigaDapagliflozin Propanediol53$74,338
JardianceEmpagliflozin51$65,826
JanuviaSitagliptin Phosphate62$59,680
RybelsusSemaglutide27$55,511
TrulicityDulaglutide17$34,591
JanumetSitagliptin Phos/Metformin Hcl25$28,710
Bydureon BciseExenatide Microspheres15$22,504
Repatha SureclickEvolocumab17$19,685
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,402
XareltoRivaroxaban31$17,119
TrulancePlecanatide15$13,348
TradjentaLinagliptin12$9,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$726$408,566316 claims
Lilly USA, LLCMounjaro, Trulicity$328$393,519350 claims
PfizerEliquis, Paxlovid$373$96,448144 claims
MerckJanuvia, Janumet$168$88,39087 claims
Boehringer IngelheimJardiance, Tradjenta$108$75,68163 claims
AstraZenecaFarxiga$1,020$74,33853 claims
GSKTrelegy Ellipta, Breo Ellipta$323$26,30543 claims
Johnson & JohnsonXarelto$101$17,11931 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$983$13,34815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Ridgefield Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →